The global DNA synthesis market was valued at USD 4.42 billion in 2025. The market is estimated at USD 4.98 billion in 2026 and is projected to reach USD 15.64 billion by 2036, at a CAGR of 12.1% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering demand from drug discovery, sequencing, and synthetic biology, the technology landscape from phosphoramidite chemistry to enzymatic platforms, cost per base and turnaround time, quality and supply requirements, pricing, the competitive landscape, and future growth opportunities.
The market, also known as the synthetic DNA or custom DNA synthesis market, includes the services, instruments, and reagents used to build user-specified DNA sequences without a natural template. Custom oligonucleotides such as primers, probes, adapters, and modified oligos, oligonucleotide pools, synthetic genes and gene fragments, codon-optimized constructs, variant and combinatorial libraries, plasmids and vectors, DNA synthesizers, and consumables including phosphoramidites, solid supports, and enzyme reagents are all in scope. The study covers products supplied for research, diagnostic, and preclinical use. GMP production of oligonucleotide and mRNA drug substance for clinical trials and commercial use, finished RNA therapeutics, nucleic acid extraction and amplification products, sequencing instruments and services, and stand-alone bioinformatics software are excluded.
Twist Bioscience Corporation, a leading synthesis provider, reported record revenue of USD 118.4 million for its fiscal third quarter ended June 30, 2026, a 23% year-on-year increase, while its DNA Synthesis and Protein Solutions revenue rose 39% to USD 56.6 million and genes shipped climbed to approximately 369,000 from approximately 237,000. Sequencing also keeps oligonucleotide demand steady, as Illumina, Inc. reported USD 775 million in second-quarter 2026 revenue from sequencing consumables, up 5%, and these workflows depend on synthetic adapters, index sequences, and enrichment probes. In July 2026, the FDA extended CASGEVY, the first approved CRISPR gene-editing therapy, to patients as young as two, which supports continued research spending on genetic medicine.
The short length that chemical synthesis can achieve is a key restraint, since longer genes must be assembled from fragments, adding time, cost, and assembly errors, and repetitive, high-GC, or highly structured sequences fail more often and need verification and correction. Standard oligos and routine genes have become commodities, and price and turnaround competition from providers in China and other Asia-Pacific countries is squeezing margins. Academic funding is also uncertain: the Consolidated Appropriations Act, 2026 set the fiscal 2026 program level of the National Institutes of Health at USD 47.49 billion, 1.0% above fiscal 2025, although an earlier proposal to cut it by more than 40% and the delay in final appropriations led many institutions to hold back discretionary purchases. Providers must also invest steadily in sequence verification, quality systems, and capacity while demand moves with funding cycles and customer milestones.
Enzymatic synthesis is a significant opportunity, since engineered enzymes working in water-based conditions promise longer sequences, fewer errors, and much less hazardous solvent waste. Integrated design-build-test services that take a customer's computational design through synthesis, protein expression, and functional screening are a second opening, along with diagnostic-grade oligonucleotide supply under documented quality agreements and local capacity in China, India, South Korea, and Southeast Asia. Key trends include falling cost per base with rising parallel throughput, closer links between AI design tools and digital ordering platforms, and a shift in orders from short oligos and single genes toward long constructs, multi-gene pathways, and ready-to-use plasmids.
By offering, the DNA synthesis market is segmented into oligonucleotide synthesis, gene synthesis, DNA synthesizers, and reagents & consumables, with oligos split into standard, modified, and pooled products and gene synthesis covering genes and fragments, libraries, and plasmids and vectors. In 2026, oligonucleotide synthesis is expected to lead the market, as oligos are used in almost every molecular biology workflow, PCR and NGS consume primers and probes in very large numbers across research and diagnostics, and academic, industrial, and diagnostic customers reorder them on a recurring basis. Gene synthesis is expected to grow at the highest CAGR during the forecast period, driven by antibody discovery, protein engineering, and AI-led design programs that order genes and variant libraries in bulk, the move toward longer constructs and complete pathways, and the sharp rise in genes shipped by providers such as Twist Bioscience.
By synthesis method, the DNA synthesis market is segmented into chemical synthesis (column-based synthesis and array- & chip-based synthesis) and enzymatic synthesis. Chemical synthesis is expected to hold the largest share in 2026, reflecting decades of industry use of phosphoramidite chemistry, a large installed base of column and array platforms, and the wide range of chemical modifications it supports. Enzymatic synthesis is expected to grow at the highest CAGR, because it can produce longer sequences with fewer errors, uses far less organic solvent and generates less hazardous waste, and is being brought to market by DNA Script, Ansa Biotechnologies, and Molecular Assemblies.
By application, the DNA synthesis market is segmented into life science research, diagnostics, therapeutics development, and industrial & synthetic biology. Life science research is expected to be the largest application in 2026, as synthetic DNA is used throughout academic, government, and industrial laboratories, sequencing and PCR workflows consume oligonucleotides continuously, and protein engineering and antibody discovery teams order genes and libraries in high volumes. Therapeutics development is expected to grow at the highest CAGR, supported by growing gene editing, cell and gene therapy, and mRNA pipelines, wider use of approved gene-editing therapies such as CASGEVY, and the many sequence variants tested in discovery and preclinical work. Life science research covers genomics & sequencing, protein engineering & antibody discovery, and other research.
By end user, the DNA synthesis market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, diagnostic laboratories & kit manufacturers, CROs & CDMOs, and industrial & synthetic biology companies. Pharmaceutical & biotechnology companies are expected to be the largest end users in 2026, given how heavily they rely on genes and libraries during discovery and preclinical work, their large R&D budgets, and their spending on antibody, protein, and genetic medicine programs. Industrial & synthetic biology companies are expected to grow at the highest CAGR, as engineered biology expands into pharmaceuticals, chemicals, food ingredients, agriculture, and materials, automated foundries build and test thousands of designs, and falling cost per construct makes large design campaigns affordable. Academic and research institutes remain a large customer base, although their purchasing follows public funding cycles.
North America is expected to remain the largest regional DNA synthesis market in 2026, as the region hosts a dense base of pharmaceutical, biotechnology, and synthetic biology companies, receives substantial public and private research funding, and leads in antibody discovery, protein engineering, and genetic medicine. Major providers such as Twist Bioscience, Integrated DNA Technologies, Thermo Fisher Scientific, Azenta, and Ansa Biotechnologies are also based in the region. Europe holds a significant position, backed by strong academic research, a large pharmaceutical sector, growing industrial biotechnology, and suppliers including Merck KGaA, Eurofins Genomics, LGC Biosearch Technologies, Kaneka Eurogentec, and DNA Script.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period. Biopharmaceutical research, CRO capacity, and molecular diagnostics are expanding quickly in China, India, South Korea, and Japan, governments are investing heavily in biotechnology and genomics, and domestic providers such as GenScript Biotech offer competitive pricing and turnaround that attract international as well as local customers. Latin America and the Middle East & Africa remain smaller markets, with academic research and agricultural biotechnology in Brazil and Mexico and genomics investment in the Gulf countries expected to support demand from a low base.
The DNA synthesis market is moderately fragmented, as established providers hold significant positions in both oligonucleotide and gene synthesis, while technology-led entrants are building enzymatic platforms and regional suppliers compete on price and speed. Buyers judge providers on turnaround time, accuracy and achievable length, cost per base, success with difficult sequences, scale, modification chemistry, quality systems, digital ordering tools, and bundled protein and screening services. Leading companies are adding high-throughput capacity, broadening gene and library portfolios, linking synthesis with expression and screening, building design software, and advancing enzymatic chemistry. Twist Bioscience, for example, reported record quarterly results and lifted its fiscal 2026 revenue guidance to USD 456-457 million.
Key companies profiled in the report include Twist Bioscience Corporation (U.S.), Danaher Corporation (Integrated DNA Technologies) (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), GenScript Biotech Corporation (China), Azenta, Inc. (GENEWIZ) (U.S.), Eurofins Scientific SE (Eurofins Genomics) (Luxembourg), LGC Limited (LGC Biosearch Technologies) (U.K.), Kaneka Eurogentec S.A. (Belgium), DNA Script SAS (France), Ansa Biotechnologies, Inc. (U.S.), and Molecular Assemblies, Inc. (U.S.).
The market, also known as the synthetic DNA or custom DNA synthesis market, includes the services, instruments, and reagents used to build user-specified DNA sequences without a natural template. Custom oligonucleotides such as primers, probes, adapters, and modified oligos, oligonucleotide pools, synthetic genes and gene fragments, codon-optimized constructs, variant and combinatorial libraries, plasmids and vectors, DNA synthesizers, and consumables including phosphoramidites, solid supports, and enzyme reagents are all in scope. The study covers products supplied for research, diagnostic, and preclinical use. GMP production of oligonucleotide and mRNA drug substance for clinical trials and commercial use, finished RNA therapeutics, nucleic acid extraction and amplification products, sequencing instruments and services, and stand-alone bioinformatics software are excluded.
Twist Bioscience Corporation, a leading synthesis provider, reported record revenue of USD 118.4 million for its fiscal third quarter ended June 30, 2026, a 23% year-on-year increase, while its DNA Synthesis and Protein Solutions revenue rose 39% to USD 56.6 million and genes shipped climbed to approximately 369,000 from approximately 237,000. Sequencing also keeps oligonucleotide demand steady, as Illumina, Inc. reported USD 775 million in second-quarter 2026 revenue from sequencing consumables, up 5%, and these workflows depend on synthetic adapters, index sequences, and enrichment probes. In July 2026, the FDA extended CASGEVY, the first approved CRISPR gene-editing therapy, to patients as young as two, which supports continued research spending on genetic medicine.
Market Dynamics
Antibody discovery, protein engineering, and AI-driven molecular design are major drivers of the DNA synthesis market, as computational models now propose far more candidate sequences per program than teams could test in the past, and each one must be built as a gene or library member. Next-generation sequencing and molecular diagnostics form a second driver, because every PCR, qPCR, and NGS assay needs sequence-specific primers, probes, adapters, and target enrichment panels; Tempus AI, Inc. reported that its oncology testing volume rose 31% in the second quarter of 2026. Synthetic biology programs in pharmaceuticals, chemicals, food ingredients, agriculture, and materials add recurring demand through repeated design-build-test cycles, while gene editing, cell and gene therapy, and mRNA research need templates, donor constructs, promoters, and linear DNA for in vitro transcription.The short length that chemical synthesis can achieve is a key restraint, since longer genes must be assembled from fragments, adding time, cost, and assembly errors, and repetitive, high-GC, or highly structured sequences fail more often and need verification and correction. Standard oligos and routine genes have become commodities, and price and turnaround competition from providers in China and other Asia-Pacific countries is squeezing margins. Academic funding is also uncertain: the Consolidated Appropriations Act, 2026 set the fiscal 2026 program level of the National Institutes of Health at USD 47.49 billion, 1.0% above fiscal 2025, although an earlier proposal to cut it by more than 40% and the delay in final appropriations led many institutions to hold back discretionary purchases. Providers must also invest steadily in sequence verification, quality systems, and capacity while demand moves with funding cycles and customer milestones.
Enzymatic synthesis is a significant opportunity, since engineered enzymes working in water-based conditions promise longer sequences, fewer errors, and much less hazardous solvent waste. Integrated design-build-test services that take a customer's computational design through synthesis, protein expression, and functional screening are a second opening, along with diagnostic-grade oligonucleotide supply under documented quality agreements and local capacity in China, India, South Korea, and Southeast Asia. Key trends include falling cost per base with rising parallel throughput, closer links between AI design tools and digital ordering platforms, and a shift in orders from short oligos and single genes toward long constructs, multi-gene pathways, and ready-to-use plasmids.
Segment Analysis
The report analyzes the market by offering, synthesis method, application, end user, and geography, helping stakeholders identify the most attractive areas for investment, capacity expansion, and partnering.By offering, the DNA synthesis market is segmented into oligonucleotide synthesis, gene synthesis, DNA synthesizers, and reagents & consumables, with oligos split into standard, modified, and pooled products and gene synthesis covering genes and fragments, libraries, and plasmids and vectors. In 2026, oligonucleotide synthesis is expected to lead the market, as oligos are used in almost every molecular biology workflow, PCR and NGS consume primers and probes in very large numbers across research and diagnostics, and academic, industrial, and diagnostic customers reorder them on a recurring basis. Gene synthesis is expected to grow at the highest CAGR during the forecast period, driven by antibody discovery, protein engineering, and AI-led design programs that order genes and variant libraries in bulk, the move toward longer constructs and complete pathways, and the sharp rise in genes shipped by providers such as Twist Bioscience.
By synthesis method, the DNA synthesis market is segmented into chemical synthesis (column-based synthesis and array- & chip-based synthesis) and enzymatic synthesis. Chemical synthesis is expected to hold the largest share in 2026, reflecting decades of industry use of phosphoramidite chemistry, a large installed base of column and array platforms, and the wide range of chemical modifications it supports. Enzymatic synthesis is expected to grow at the highest CAGR, because it can produce longer sequences with fewer errors, uses far less organic solvent and generates less hazardous waste, and is being brought to market by DNA Script, Ansa Biotechnologies, and Molecular Assemblies.
By application, the DNA synthesis market is segmented into life science research, diagnostics, therapeutics development, and industrial & synthetic biology. Life science research is expected to be the largest application in 2026, as synthetic DNA is used throughout academic, government, and industrial laboratories, sequencing and PCR workflows consume oligonucleotides continuously, and protein engineering and antibody discovery teams order genes and libraries in high volumes. Therapeutics development is expected to grow at the highest CAGR, supported by growing gene editing, cell and gene therapy, and mRNA pipelines, wider use of approved gene-editing therapies such as CASGEVY, and the many sequence variants tested in discovery and preclinical work. Life science research covers genomics & sequencing, protein engineering & antibody discovery, and other research.
By end user, the DNA synthesis market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, diagnostic laboratories & kit manufacturers, CROs & CDMOs, and industrial & synthetic biology companies. Pharmaceutical & biotechnology companies are expected to be the largest end users in 2026, given how heavily they rely on genes and libraries during discovery and preclinical work, their large R&D budgets, and their spending on antibody, protein, and genetic medicine programs. Industrial & synthetic biology companies are expected to grow at the highest CAGR, as engineered biology expands into pharmaceuticals, chemicals, food ingredients, agriculture, and materials, automated foundries build and test thousands of designs, and falling cost per construct makes large design campaigns affordable. Academic and research institutes remain a large customer base, although their purchasing follows public funding cycles.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 17 countries and four rest-of-region groups. The regional analysis considers the concentration of pharmaceutical, biotechnology, and synthetic biology companies, research funding, diagnostics activity, and the location of synthesis capacity and providers.North America is expected to remain the largest regional DNA synthesis market in 2026, as the region hosts a dense base of pharmaceutical, biotechnology, and synthetic biology companies, receives substantial public and private research funding, and leads in antibody discovery, protein engineering, and genetic medicine. Major providers such as Twist Bioscience, Integrated DNA Technologies, Thermo Fisher Scientific, Azenta, and Ansa Biotechnologies are also based in the region. Europe holds a significant position, backed by strong academic research, a large pharmaceutical sector, growing industrial biotechnology, and suppliers including Merck KGaA, Eurofins Genomics, LGC Biosearch Technologies, Kaneka Eurogentec, and DNA Script.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period. Biopharmaceutical research, CRO capacity, and molecular diagnostics are expanding quickly in China, India, South Korea, and Japan, governments are investing heavily in biotechnology and genomics, and domestic providers such as GenScript Biotech offer competitive pricing and turnaround that attract international as well as local customers. Latin America and the Middle East & Africa remain smaller markets, with academic research and agricultural biotechnology in Brazil and Mexico and genomics investment in the Gulf countries expected to support demand from a low base.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard (market leaders, market differentiators, vanguards, and emerging players), and market share/rank analysis by key player for 2025. Company profiles include business overviews, financial overviews, DNA synthesis and product/service portfolios, strategic developments, and SWOT analyses.The DNA synthesis market is moderately fragmented, as established providers hold significant positions in both oligonucleotide and gene synthesis, while technology-led entrants are building enzymatic platforms and regional suppliers compete on price and speed. Buyers judge providers on turnaround time, accuracy and achievable length, cost per base, success with difficult sequences, scale, modification chemistry, quality systems, digital ordering tools, and bundled protein and screening services. Leading companies are adding high-throughput capacity, broadening gene and library portfolios, linking synthesis with expression and screening, building design software, and advancing enzymatic chemistry. Twist Bioscience, for example, reported record quarterly results and lifted its fiscal 2026 revenue guidance to USD 456-457 million.
Key companies profiled in the report include Twist Bioscience Corporation (U.S.), Danaher Corporation (Integrated DNA Technologies) (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), GenScript Biotech Corporation (China), Azenta, Inc. (GENEWIZ) (U.S.), Eurofins Scientific SE (Eurofins Genomics) (Luxembourg), LGC Limited (LGC Biosearch Technologies) (U.K.), Kaneka Eurogentec S.A. (Belgium), DNA Script SAS (France), Ansa Biotechnologies, Inc. (U.S.), and Molecular Assemblies, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global DNA synthesis market.
- Explains how antibody discovery, AI-driven design, NGS diagnostics, synthetic biology, and genetic medicine research are shaping demand.
- Assesses the effect of length and accuracy limits, price competition, and research funding variability on providers.
- Identifies high-growth opportunities across offering, synthesis method, application, end user, and region.
- Tracks enzymatic synthesis, high-throughput array platforms, and integrated design-build-test services.
- Benchmarks leading providers on turnaround, accuracy, cost per base, quality systems, and service breadth.
- Supports capacity planning, product strategy, partnering, and market entry decisions for synthesis providers, instrument and reagent suppliers, and investors.
Key Questions Answered
- How big is the global DNA synthesis market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are AI-driven design and high-throughput screening changing demand for genes and variant libraries?
- How do cost per base and turnaround time compare across synthesis platforms?
- How does enzymatic synthesis compare with chemical synthesis, and how fast will it be adopted?
- Which offering, application, and end user segments will grow the fastest?
- What quality and supply requirements do diagnostic and preclinical customers place on providers?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and what strategies are they pursuing?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. DNA Synthesis Market Assessment, by Offering
6. DNA Synthesis Market Assessment, by Synthesis Method
7. DNA Synthesis Market Assessment, by Application
8. DNA Synthesis Market Assessment, by End User
9. DNA Synthesis Market Assessment, by Geography
10. Competition Analysis
11. Company Profiles
12. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Twist Bioscience Corporation
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Merck KGaA
- GenScript Biotech Corporation
- Azenta, Inc.
- Eurofins Scientific SE
- LGC Limited
- Kaneka Eurogentec S.A.
- DNA Script SAS
- Ansa Biotechnologies, Inc.
- Molecular Assemblies, Inc.
